Finerenone significantly reduced the combined risk of cardiovascular death and total (first and recurrent) heart failure events,
The product will be launched in Q1FY26
GE HealthCare’s Revolution Vibe CT enables more facilities to elevate patient care by offering advanced cardiac imaging technology
Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients with heart failure
Dabigatran Etexilate Capsules are indicated for reduction of risk of stroke and systemic embolism in non-valvular atrial fibrillation in adult patients
Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Subscribe To Our Newsletter & Stay Updated